Literature DB >> 33860682

Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System.

Adriana Galvan1, Terri L Petkau2, Austin M Hill2, Andrea J Korecki2, Ge Lu2, Diane Choi1,3, Kazi Rahman1, Elizabeth M Simpson2,4, Blair R Leavitt2,4,5,6, Yoland Smith1.   

Abstract

Viral vectors made from adeno-associated virus (AAV) have emerged as preferred tools in basic and translational neuroscience research to introduce or modify genetic material in cells of interest. The use of viral vectors is particularly attractive in nontransgenic species, such as nonhuman primates. Injection of AAV solutions into the cerebrospinal fluid is an effective method to achieve a broad distribution of a transgene in the central nervous system. In this study, we conducted injections of AAV9-PHP.B, a recently described AAV capsid mutant, in the lateral ventricle of mice and rhesus macaques. To enhance the expression of the transgene (the tag protein emerald green fluorescent protein [EmGFP]), we used a gene promoter that confers high neuron-specific expression of the transgene, the human synapsin 1 (SYN1) promoter. The efficacy of the viral vector was first tested in mice. Our results show that intracerebroventricular injections of AAV9-PHP.B SYN1-EmGFP-woodchuck hepatitis virus posttranscriptional regulatory element resulted in neuronal EmGFP expression throughout the mice and monkey brains. We have provided a thorough characterization of the brain regions expressing EmGFP in both species. EmGFP was observed in neuronal cell bodies over the whole cerebral cortex and in the cerebellum, as well as in some subcortical regions, including the striatum and hippocampus. We also observed densely labeled neuropil in areas known to receive projections from these regions. Double fluorescence studies demonstrated that EmGFP was expressed by several types of neurons throughout the mouse and monkey brain. Our results demonstrate that a single injection in the lateral ventricle is an efficient method to obtain transgene expression in many cortical and subcortical regions, obviating the need of multiple intraparenchymal injections to cover large brain areas. The use of intraventricular injections of AAV9-PHP.B SYN1-EmGFP could provide a powerful approach to transduce widespread areas of the brain and may contribute to further development of methods to genetically target-specific populations of neurons.

Entities:  

Keywords:  ICV; adeno-associated virus; gene therapy; primate; synapsin

Mesh:

Substances:

Year:  2021        PMID: 33860682      PMCID: PMC8236560          DOI: 10.1089/hum.2020.301

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   4.793


  47 in total

1.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.

Authors:  William A Liguore; Jacqueline S Domire; Dana Button; Yun Wang; Brett D Dufour; Sathya Srinivasan; Jodi L McBride
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

2.  The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.

Authors:  Juliette Hordeaux; Qiang Wang; Nathan Katz; Elizabeth L Buza; Peter Bell; James M Wilson
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

Review 3.  Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.

Authors:  Joana Saraiva; Rui Jorge Nobre; Luis Pereira de Almeida
Journal:  J Control Release       Date:  2016-09-13       Impact factor: 9.776

4.  AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.

Authors:  Lluis Samaranch; Waldy San Sebastian; Adrian P Kells; Ernesto A Salegio; Gregory Heller; John R Bringas; Philip Pivirotto; Stephen DeArmond; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2013-11-21       Impact factor: 11.454

5.  Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.

Authors:  Marco A Passini; Jie Bu; Amy M Richards; Christopher M Treleaven; Jennifer A Sullivan; Catherine R O'Riordan; Abraham Scaria; Adrian P Kells; Lluis Samaranch; Waldy San Sebastian; Thais Federici; Massimo S Fiandaca; Nicholas M Boulis; Krystof S Bankiewicz; Lamya S Shihabuddin; Seng H Cheng
Journal:  Hum Gene Ther       Date:  2014-04-28       Impact factor: 5.695

6.  Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna.

Authors:  Christian Hinderer; Peter Bell; Charles H Vite; Jean-Pierre Louboutin; Rebecca Grant; Erin Bote; Hongwei Yu; Bryan Pukenas; Robert Hurst; James M Wilson
Journal:  Mol Ther Methods Clin Dev       Date:  2014-12-10       Impact factor: 6.698

7.  rAAV-compatible MiniPromoters for restricted expression in the brain and eye.

Authors:  Charles N de Leeuw; Andrea J Korecki; Garrett E Berry; Jack W Hickmott; Siu Ling Lam; Tess C Lengyell; Russell J Bonaguro; Lisa J Borretta; Vikramjit Chopra; Alice Y Chou; Cletus A D'Souza; Olga Kaspieva; Stéphanie Laprise; Simone C McInerny; Elodie Portales-Casamar; Magdalena I Swanson-Newman; Kaelan Wong; George S Yang; Michelle Zhou; Steven J M Jones; Robert A Holt; Aravind Asokan; Daniel Goldowitz; Wyeth W Wasserman; Elizabeth M Simpson
Journal:  Mol Brain       Date:  2016-05-10       Impact factor: 4.041

8.  PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation.

Authors:  Yuji Nagai; Erika Kikuchi; Walter Lerchner; Ken-Ichi Inoue; Bin Ji; Mark A G Eldridge; Hiroyuki Kaneko; Yasuyuki Kimura; Arata Oh-Nishi; Yukiko Hori; Yoko Kato; Toshiyuki Hirabayashi; Atsushi Fujimoto; Katsushi Kumata; Ming-Rong Zhang; Ichio Aoki; Tetsuya Suhara; Makoto Higuchi; Masahiko Takada; Barry J Richmond; Takafumi Minamimoto
Journal:  Nat Commun       Date:  2016-12-06       Impact factor: 14.919

9.  Efficient integration of transgenes into a defined locus in human embryonic stem cells.

Authors:  Kenji Sakurai; Miho Shimoji; Candice G T Tahimic; Kazuhiro Aiba; Eihachiro Kawase; Kouichi Hasegawa; Yuji Amagai; Hirofumi Suemori; Norio Nakatsuji
Journal:  Nucleic Acids Res       Date:  2010-01-13       Impact factor: 16.971

Review 10.  Biology of adeno-associated viral vectors in the central nervous system.

Authors:  Giridhar Murlidharan; Richard J Samulski; Aravind Asokan
Journal:  Front Mol Neurosci       Date:  2014-09-19       Impact factor: 5.639

View more
  6 in total

Review 1.  Applications of chemogenetics in non-human primates.

Authors:  Jessica Raper; Adriana Galvan
Journal:  Curr Opin Pharmacol       Date:  2022-03-17       Impact factor: 4.768

Review 2.  Nonhuman Primates in Translational Research.

Authors:  Alice F Tarantal; Stephen C Noctor; Dennis J Hartigan-O'Connor
Journal:  Annu Rev Anim Biosci       Date:  2022-02-15       Impact factor: 13.341

3.  PAM-flexible dual base editor-mediated random mutagenesis and self-activation strategies to improve CRISPRa potency.

Authors:  Cia-Hin Lau; Siping Huang; Raymond H W Lam; Chung Tin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-29       Impact factor: 5.849

Review 4.  Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Biomedicines       Date:  2022-03-23

Review 5.  AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.

Authors:  Marika Marino; Matthew G Holt
Journal:  Front Neurol       Date:  2022-04-12       Impact factor: 4.086

Review 6.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.